サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1529371

性器ヘルペス治療の世界市場：2024-2031年

Global Genital Herpes Treatment Market - 2024-2031

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
性器ヘルペス治療の世界市場：2024-2031年
出版日: 2024年08月06日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の性器ヘルペス治療市場は、2023年に11億4,319万米ドルに達し、2031年には16億6,981万米ドルに達すると予測され、予測期間2024年にはCAGR 4.8%で成長すると予測されています。

性器ヘルペスは、単純ヘルペスウイルス（HSV）、特にHSV-2型によって引き起こされる性感染症（STD）です。性器や直腸、臀部、大腿部にただれを生じさせる。感染は、感染者との性的接触によって感染します。性器ヘルペスの合併症は、他の性病に感染しやすいこと、新生児感染症、内臓炎症性疾患、眼感染症、まれに脳の腫れや内臓の感染などがあります。現在のところ、性器ヘルペスを治療する方法はなく、治療の主流はアシクロビル、ファムシクロビル、バラシクロビル、ペンシクロビルなどの抗ウイルス薬です。

市場力学：

促進要因

研究開発とパイプライン製品の増加

現在、米国食品医薬品局（FDA）が承認している性器ヘルペス治療薬は限られています。これらの薬剤には、アシクロビル、ファムシクロビル、バラシクロビル、ペンシクロビルなどがあり、一般的に使用されている抗ウイルス剤です。この疾患の有病率が上昇しているにもかかわらず、治療の選択肢は限られており、新規薬剤に対する需要が生じています。いくつかのメーカーは、性器ヘルペスに特化した新薬の開発に投資しています。これらの医薬品が市場に投入されれば、市場力学に大きな影響を与える可能性があります。

例えば、AiCuris Anti-infective Cures AGは、アシクロビル耐性またはアシクロビル感受性の粘膜皮膚HSV感染症を有する免疫不全被験者の性器ヘルペス治療用の新規抗ウイルス薬であるPritelivirを開発しています。同剤は現在、臨床第3相試験中であり、2025年半ばまでに試験を終了する予定です。

GSK plc.は、18歳以上の成人における性器ヘルペスの再発抑制を目的として、新規組換えタンパク質GSK3943104を開発しています。この新規製品は現在第2相臨床試験中で、2026年半ばまでに終了する予定です。

Moderna, Inc.は、再発性HSV-2性器ヘルペスを有する18歳から55歳の健康成人を対象に、新規mRNAワクチンmRNA-1608を研究しています。この治験用ワクチンは現在第1/2相臨床試験中であり、2025年半ばまでに終了する予定です。

さらに、BioNTech SEは、性器ヘルペスを予防するためのBNT163を第1相臨床試験で研究しています。BNT163は、HSV-2に対する能動免疫のための抗ウイルス性リボ核酸（RNA）ワクチンで、筋肉内注射として投与されます。この研究は2025年末までに終了する予定です。

加えて、性器ヘルペスの有病率の上昇、認知度を高めるための政府のイニシアチブの高まりが、予測期間中の市場成長をさらに促進すると予想されています。

抑制要因

性器ヘルペスなどの性感染症（STD）を取り巻く社会的スティグマは、治療市場の成長を著しく抑制します。スティグマは、過少報告や誤診、診断の遅れ、限られた社会的認識、検査量の減少につながり、最終的に治療を選択する患者数を減少させます。さらに、患者によっては無症状であるため、治療を選択する患者数が制限される可能性もあります。

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 性器ヘルペスの有病率の上昇
      • 政府のイニシアチブの高まり
    • 抑制要因
      • 社会的烙印による過少報告
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第6章 タイプ別

  • HSV-1 性器ヘルペス
  • HSV-2 性器ヘルペス

第7章 薬剤タイプ別

  • アシクロビル
  • バラシクロビル
  • ファムシクロビル
  • その他

第8章 投与経路別

  • 経口
  • 非経口
  • 局所
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Bausch Health Companies Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • LNHC, Inc.
  • GSK plc.
  • Camber Pharmaceuticals, Inc.
  • Rising Pharma Holdings, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Padagis
  • Viatris Inc.
  • AdvaCare Pharma
  • Sun Pharmaceutical Industries Ltd.

第13章 付録

目次
Product Code: PH8561

Overview

The global genital herpes treatment market reached US$ 1,143.19 million in 2023 and is expected to reach US$ 1,669.81 million by 2031, growing at a CAGR of 4.8% during the forecast period 2024-2031.

Genital herpes is a sexually transmitted disease (STD) caused by the herpes simplex virus (HSV) especially HSV type 2. It can cause sores in the genital or rectal area, buttocks, and thighs. The infection transmits through sexual contact with the infected person. The complications of genital herpes are easy contraction of other STIs, newborn infections, internal inflammatory disease, eye infection, and rarely swelling of brain and infection in the internal organs. There is currently no cure for genital herpes, the mainstay of treatment includes antiviral drugs such as acyclovir, famciclovir, valacyclovir and penciclovir.

Market Dynamics: Drivers

Rising research and development activities and pipeline products

Currently, the U.S. Food and Drug Administration (FDA) has approved only a limited number of drugs for the treatment of genital herpes. These drugs include acyclovir, famciclovir, valacyclovir, and penciclovir, the commonly used antiviral drugs. Despite the rising prevalence of the condition, the therapeutic options are limited creating a demand for novel drugs. Several manufacturers have been investing in and developing novel drugs that specifically aim for genital herpes. These drugs, if entered into the market, may create a huge impact on the market dynamics.

For instance, AiCuris Anti-infective Cures AG has been developing Pritelivir a novel anti-viral drug for the treatment of genital herpes in immunocompromised subjects with acyclovir-resistant or acyclovir-susceptible mucocutaneous HSV infection. The drug is currently in an investigational phase 3 study and is anticipated to finish the trial by the mid of 2025.

GSK plc. Has been developing a novel recombinant protein GSK3943104 for the suppression of recurrent genital herpes in adults aged 18 years and older. The novel product is currently in phase 2 clinical trial which is anticipated to be finished by mid of 2026.

Moderna, Inc. has been investigating a novel mRNA vaccine mRNA-1608 in healthy adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The investigational vaccine is currently in phase 1/2 clinical trial and is estimated to be finished by mid of 2025.

Moreover, BioNTech SE has been investigating BNT163 in a phase 1 clinical trial to prevent genital herpes. BNT163 is an anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as an intramuscular injection. The study is anticipated to be finished by the end of 2025.

In addition, the rising prevalence of genital herpes, rising government initiatives to increase the awareness are expected to further propel the market growth in the forecast period.

Restraints

The social stigma surrounding sexually transmitted diseases (STDs), such as genital herpes, significantly hinders the growth of the treatment market. Stigma leads to underreporting and misdiagnosis, delayed diagnosis, limited public awareness, and reduced testing volume which ultimately reduce the number of patients opting for treatment. Moreover, the asymptomatic nature of the conditions in some patients may limit the patient population opting for treatment.

For more details on this report - Request for Sample

Segment Analysis

The global genital herpes treatment market is segmented based on type, drug type, route of administration, distribution channel, and region.

The acyclovir in the drug type segment accounted for approximately 56.6% of the global genital herpes treatment market share

Acyclovir, a long-standing antiviral medication, has proven effective in treating genital herpes, reducing outbreak severity and duration. Its safety profile and efficacy have been extensively studied, making it a trusted treatment option. Acyclovir is available in multiple formulations, including oral tablets, topical creams, and intravenous formulations, making it versatile, and suitable for treating a variety of patients. Moreover, the drug is manufactured by many well-known pharmaceutical companies and is available globally.

It is recommended as a first-line treatment for genital herpes due to its effectiveness, tolerability, and established safety profile. According to the World Health Organization (WHO) STI guidelines, For adults and adolescents with a first clinical episode of genital HSV infection, the preferred drug is a standard dose of aciclovir over valaciclovir or famciclovir. In addition, acyclovir is also used in suppressive therapy to reduce outbreak frequency, making it suitable for individuals with recurrent genital herpes.

Geographical Analysis

North America has a significant market share of 43.3% in the global genital herpes treatment market.

The prevalence of genital herpes is highest in the North American region, especially in the U.S. which is a strong contributor of the regions market dominance. For instance, as per a cohort study conducted in the U.S. from 2019 to 2021, published in the Journal of the American Sexually Transmitted Diseases Association (ASTDA), the standardized prevalence of diagnosed genital herpes and recurrent genital herpes ranged from 236 to 280 cases per 100,000 person-years and 81 to 98 cases per 100,000 person-years, respectively. As per DataM estimates, the prevalent cases of genital herpes in the U.S. from 2019 to 2023 are as follows.

Moreover, the region is well known for its advanced healthcare infrastructure. The patients have access to care with ease, and the healthcare facilities provide a plethora of treatment options. Moreover, the availability of drugs both in branded and generic forms provides affordable options to patients in the region. In addition, the awareness campaigns by health agencies, government bodies, and NGOs in the region, create a huge impact on society which results in higher treatment rates as compared to any other region.

Market Segmentation

By Type

  • HSV-1 Genital Herpes
  • HSV-2 Genital Herpes

By Drug Type

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major players in the genital herpes treatment market include Bausch Health Companies Inc., LNHC, Inc., GSK plc., Camber Pharmaceuticals, Inc., Rising Pharma Holdings, Inc., Teva Pharmaceuticals USA, Inc., Padagis, Viatris Inc., AdvaCare Pharma, and Sun Pharmaceutical Industries Ltd. among others.

Why Purchase the Report?

  • To visualize the global genital herpes treatment market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of genital herpes treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global genital herpes treatment market report would provide approximately 70 tables,63 figures, and 187 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of genital herpes
      • 4.1.1.2. Rising government initiatives
    • 4.1.2. Restraints
      • 4.1.2.1. Under-reporting due to social stigma
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. HSV-1 Genital Herpes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. HSV-2 Genital Herpes

7. By Drug type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Acyclovir*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Valacyclovir
  • 7.4. Famciclovir
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Topical
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. The U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
      • 10.3.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.2. Germany
      • 10.3.6.3. UK
      • 10.3.6.4. France
      • 10.3.6.5. Italy
      • 10.3.6.6. Spain
      • 10.3.6.7. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
      • 10.4.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.2. Brazil
      • 10.4.6.3. Argentina
      • 10.4.6.4. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
      • 10.5.6.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.2. China
      • 10.5.6.3. India
      • 10.5.6.4. Japan
      • 10.5.6.5. South Korea
      • 10.5.6.6. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bausch Health Companies Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. LNHC, Inc.
  • 12.3. GSK plc.
  • 12.4. Camber Pharmaceuticals, Inc.
  • 12.5. Rising Pharma Holdings, Inc.
  • 12.6. Teva Pharmaceuticals USA, Inc.
  • 12.7. Padagis
  • 12.8. Viatris Inc.
  • 12.9. AdvaCare Pharma
  • 12.10. Sun Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us